About Lantheus Holdings, Inc. - Common Stock (LNTH)
Lantheus Holdings is a biotechnology company that specializes in developing and commercializing innovative diagnostic imaging agents and therapeutics primarily for oncology and other conditions. Their products include advanced molecular imaging agents that enhance the visualization of diseases in patients, enabling healthcare providers to make more informed decisions about diagnosis and treatment. The company is committed to advancing patient care through its focus on precision medicine, utilizing cutting-edge technologies to improve the detection and management of various diseases, particularly cancers, thus helping clinicians optimize patient outcomes. Read More
The Law Offices of Frank R. Cruz announces an investigation of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) on behalf of investors concerning the Company’s possible violations of federal securities laws.
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”), have until November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. Captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.), the Lantheus class action lawsuit charges Lantheus and certain of Lantheus’s top executives with violations of the Securities Exchange Act of 1934.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025. Lantheus describes itself as a “global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products.”
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH) investors concerning the Company’s possible violation of the federal securities laws or other unlawful business practices.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (NASDAQ:PRAX), Align Technology, Inc. (NASDAQ:ALGN), Lantheus Holdings, Inc. (NASDAQ:LNTH), and Spirit Aviation Holdings, Inc. (NYSE:FLYY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Lantheus Holdings (LNTH) is a value stock with a low P/E ratio, strong financial health, and high profitability, making it an attractive opportunity for value investors.
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9.
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) for violations of the securities laws.
RADNOR, PA - August 23, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Lantheus Holdings, Inc. ( NASDAQ: LNTH ) (“Lantheus”).
NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). The investigation concerns whether Lantheus and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
RADNOR, PA - August 22, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Lantheus Holdings, Inc. ( NASDAQ: LNTH ) (“Lantheus”).
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 3.1% on continued negative momentum after a downgrade by Truist Securities, which cited concerns over competitive pressures and weaker-than-expected second-quarter results. The downgrade from "Buy" to "Hold" by Truist Securities included a significant price target reduction to $63 from $111.
